Virios Therapeutics, Inc. (NASDAQ:VIRI – Get Free Report) shares traded down 0.6% during trading on Wednesday . The company traded as low as $1.7240 and last traded at $1.78. 84,121 shares changed hands during mid-day trading, a decline of 92% from the average session volume of 1,049,645 shares. The stock had previously closed at $1.79.
Virios Therapeutics Stock Down 0.6%
The company has a market capitalization of $34.28 million, a P/E ratio of -6.59 and a beta of 1.58. The company has a 50-day moving average of $1.95 and a two-hundred day moving average of $3.43.
About Virios Therapeutics
Virios Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for fibrotic diseases. The company leverages its proprietary small-molecule platform to identify and advance compounds designed to modulate key pathways involved in scar formation and tissue repair. By concentrating on conditions with high unmet medical need, Virios aims to improve patient outcomes through more effective and safer treatment options.
The company’s lead development candidate, VTI-1002, is an oral small molecule inhibitor in clinical trials for the prevention and treatment of hypertrophic scars and keloids.
See Also
- Five stocks we like better than Virios Therapeutics
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
